OncoImmune, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Rockville MD United States (2000)
Status: Acquired by Merck (2020)

Organization Overview

First Clinical Trial
2014
NCT02650895
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

OncoImmune, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Coronavirus Infections (Phase 3)

Dyslipidemias (Phase 2)

Graft vs Host Disease (Phase 3)

Inflammation (Phase 2)

Leukemia (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 9